Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2026-05-15 Annual Report
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
FORM 20-F
Annual Report FY 2025
2026-05-15 English
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Annual Report Classification · 95% confidence The document is an ad hoc announcement pursuant to Art. 53 LR, dated April 30, 2026, reporting full-year 2025 financial results and providing a corporate update. It includes detailed financial data for the year ended December 31, 2025, such as income, expenses, net loss, cash position, and shareholders' equity. It also references the full-year 2025 financial report available on the company's website and announces a conference call to discuss the financial results. The document contains substantive financial data and analysis for the full fiscal year 2025, indicating it is a comprehensive annual financial report rather than a brief earnings release or a report publication announcement. The presence of detailed financial statements and management commentary aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2025
2026-04-30 English
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Addex Therapeutics Ltd, with the SEC. It references a press release dated April 29, 2026, which is attached as Exhibit 99.1 and incorporated by reference. The text includes risk factors referencing the company's Annual Report on Form 20-F for the year ended December 31, 2024, but does not contain actual financial statements or substantive financial data itself. The document is relatively short (4614 characters) and primarily serves as a regulatory filing to report the press release and incorporate it by reference. There is no detailed financial report or earnings data presented. According to the rules, this type of document is best classified as a Regulatory Filing (RNS), as it does not constitute a full report but rather a filing that includes or references other documents.
2026-04-29 English
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Regulatory Filings Classification · 82% confidence The document is an “Ad Hoc Announcement Pursuant to Art. 53 LR” disclosing preclinical data on a drug candidate’s antitussive activity. It is a press release required under listing rules, not an earnings release, report, or financial transaction. There is no detailed financial report, voting results, or call transcript present. It doesn’t fit any specialized category (10-K, ER, IR, CAP, etc.), so it falls into the fallback “Regulatory Filings” category.
2026-04-29 English
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Addex Therapeutics Ltd, with the SEC. It references a press release dated April 23, 2026, attached as Exhibit 99.1, which is incorporated by reference. The text includes risk factors and mentions the Annual Report on Form 20-F for the year ended December 31, 2024, but does not contain the report itself or substantive financial data. The document is primarily an announcement and incorporation by reference of a press release, not the full report or financial statements. The length is 4603 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL RULE and the nature of Form 6-K filings, this document is best classified as a Regulatory Filing (RNS).
2026-04-23 English
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
Regulatory Filings Classification · 85% confidence The document is an ad hoc announcement under Art. 53 LR on a SIX‐listed biotech’s website. It provides a business update (Phase 1 clinical study progress for its spin‐out company Neurosterix) and mentions past financing but is not a formal financial/earnings report, interim report, or investor presentation. It is not an M&A notice, delisting, director dealing, or dividend notice. It is a general regulatory announcement that does not neatly fit another specific category, so it defaults to Regulatory Filings (RNS).
2026-04-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.